Literature DB >> 9356014

Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action.

S Kapur1, S Bédard, B Marcotte, C H Côté, A Marette.   

Abstract

Previous studies have shown that nitric oxide synthase (NOS), the enzyme that catalyzes the formation of nitric oxide (NO), is expressed in skeletal muscle. The aim of the present study was to test the hypothesis that NO can modulate glucose metabolism in slow- and fast-twitch skeletal muscles. Calcium-dependent NOS was detected in skeletal muscle, and the enzyme activity was greater in fast-type extensor digitorum longus (EDL) muscles than in slow-type soleus muscles. Both the neuronal-type (nNOS) and endothelial-type (eNOS) enzymes are expressed in resting skeletal muscles. However, nNOS protein was only detected in EDL muscles, whereas eNOS protein contents were comparable in soleus and EDL muscles. NOS expression in muscle cryosections (diaphorase histochemistry) was located in vascular endothelium and in muscle fibers, and the staining was greater in type IIb than in type I and IIa fibers. The macrophage-type inducible NOS (iNOS) was not detected in resting muscle, but endotoxin treatment induced its expression, concomitant with elevated NO production. iNOS induction was associated with impaired insulin-stimulated glucose uptake in isolated rat muscles. In vitro, NOS blockade with specific inhibitors did not affect basal or insulin-stimulated glucose transport in EDL or soleus muscles. In contrast, the NO donors GEA 5024 and sodium nitroprusside induced dose-dependent inhibition (up to 50%) of maximal insulin-stimulated glucose transport in both muscles with minor effects on basal uptake values. GEA 5024 also blunted insulin-stimulated glucose transport and amino acid uptake in cultured L6 muscle cells without affecting insulin binding to its receptor. On the other hand, the permeable cGMP analogue dibutyryl cGMP did not affect muscle glucose transport. These results strongly suggest that NO modulates insulin action in both slow- and fast-type skeletal muscles. This novel autocrine action of NO in muscle appears to be mediated by cGMP-independent pathways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356014     DOI: 10.2337/diab.46.11.1691

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  52 in total

Review 1.  Cellular and molecular regulation of cardiac glucose transport.

Authors:  L H Young; D L Coven; R R Russell
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

2.  T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo.

Authors:  Hema Mahajan; Stephen M Richards; Stephen Rattigan; Michael G Clark
Journal:  Br J Pharmacol       Date:  2003-10-27       Impact factor: 8.739

3.  eNOS deletion impairs mitochondrial quality control and exacerbates Western diet-induced NASH.

Authors:  Ryan D Sheldon; Grace M Meers; E Matthew Morris; Melissa A Linden; Rory P Cunningham; Jamal A Ibdah; John P Thyfault; M Harold Laughlin; R Scott Rector
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-07-30       Impact factor: 4.310

4.  The effect of nitric oxide on glucose metabolism.

Authors:  Dalip Ragoobirsingh; Donovan McGrowder; Tara Dasgupta; Paul Brown
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

5.  Endotoxin and interferon-gamma inhibit translation in skeletal muscle cells by stimulating nitric oxide synthase activity.

Authors:  Robert A Frost; Gerald J Nystrom; Charles H Lang
Journal:  Shock       Date:  2009-10       Impact factor: 3.454

6.  Overexpression of Rad in muscle worsens diet-induced insulin resistance and glucose intolerance and lowers plasma triglyceride level.

Authors:  Jacob Ilany; Philip J Bilan; Sonia Kapur; James S Caldwell; Mary-Elizabeth Patti; Andre Marette; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

7.  Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation.

Authors:  Jin Hee Lee; Thomas Palaia; Louis Ragolia
Journal:  Am J Physiol Cell Physiol       Date:  2008-12-03       Impact factor: 4.249

8.  Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms.

Authors:  Alfredo Csibi; David Communi; Nathalie Müller; Serge P Bottari
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

9.  Nitric oxide synthesis is reduced in subjects with type 2 diabetes and nephropathy.

Authors:  Paolo Tessari; Diego Cecchet; Alessandra Cosma; Monica Vettore; Anna Coracina; Renato Millioni; Elisabetta Iori; Lucia Puricelli; Angelo Avogaro; Monica Vedovato
Journal:  Diabetes       Date:  2010-05-18       Impact factor: 9.461

10.  Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins.

Authors:  Alexandre Charbonneau; André Marette
Journal:  Diabetes       Date:  2010-01-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.